computer‐generated randomisation schedule (Glaxo Smith)
90
Structured Review
Glaxo Smith
computer‐generated randomisation schedule
Lacerda 2019 " width="250" height="auto" />
Computer‐Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+schedule/pmc08094590-85-16-20
Average 90 stars, based on 1 article reviews
Lacerda 2019 " width="250" height="auto" />Computer‐Generated Randomisation Schedule, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/computer+generated+randomisation+schedule/computer+generated+randomization+schedule/pmc08094590-85-16-20
Average 90 stars, based on 1 article reviews
computer‐generated randomisation schedule - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "Tafenoquine for preventing relapse in people with Plasmodium vivax malaria"
Article Title: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria
Journal: The Cochrane Database of Systematic Reviews
doi: 10.1002/14651858.CD010458.pub3
Lacerda 2019 " title="Lacerda 2019" property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet:
Techniques Used: Activity Assay, Infection, Sequencing, Selection
Llanos‐Cuentas 2014 " title="Llanos‐Cuentas 2014" property="contentUrl" width="100%" height="100%"/>
Figure Legend Snippet:
Techniques Used: Activity Assay, Infection, Sequencing, Selection, Generated
Related Articles
Generated:Article Title: Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial Article Snippet: Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA (F M Marty MD); Servei d’Urgències, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain (J Vidal-Puigserver PhD); Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI, USA (C Clark MD); M V Hospital & Research Centre, Lucknow, India (S K Gupta MD); Hospital General Universitario de Alicante, Alicante, Spain (E Merino PhD); Service de Réanimation Polyvalente, Hôpital Bretonneau, Tours, France (D Garot MD); Royal Adelaide Hospital, Adelaide, Australia (M J Chapman PhD); Infectious Diseases Department, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium (F Jacobs PhD); Infectología, Hospital Civil de Guadalajara Fray Antonio Alcalde; Instituto de Patología Infecciosa y Experimental, CUCS, UDG Guadalajara, Jalisco, Mexico (E Rodriguez-Noriega PhD); Department of Infectious Diseases, Faculty of Medicine, Masaryk University; University Hospital Brno, Czech Republic (P Husa PhD); PAREXEL International, Research Triangle Park, NC, USA (D Shortino MS); GlaxoSmithKline, Stockley Park, Middlesex, UK (H A Watson MSc); GlaxoSmithKline, Stevenage, Herts, UK (P J Yates PhD); and GlaxoSmithKline, Boston, MA, USA (A F Peppercorn MD) Intravenous zanamivir or oral oseltamivir for hospitalised patients with infl uenza: an international, randomised, double-blind, double-dummy, phase 3 trial Article Title: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Article Snippet: Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen Software:Article Title: Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial Article Snippet: Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA (F M Marty MD); Servei d’Urgències, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain (J Vidal-Puigserver PhD); Department of Emergency Medicine, William Beaumont Hospital, Royal Oak, MI, USA (C Clark MD); M V Hospital & Research Centre, Lucknow, India (S K Gupta MD); Hospital General Universitario de Alicante, Alicante, Spain (E Merino PhD); Service de Réanimation Polyvalente, Hôpital Bretonneau, Tours, France (D Garot MD); Royal Adelaide Hospital, Adelaide, Australia (M J Chapman PhD); Infectious Diseases Department, CUB-Erasme, Université Libre de Bruxelles, Brussels, Belgium (F Jacobs PhD); Infectología, Hospital Civil de Guadalajara Fray Antonio Alcalde; Instituto de Patología Infecciosa y Experimental, CUCS, UDG Guadalajara, Jalisco, Mexico (E Rodriguez-Noriega PhD); Department of Infectious Diseases, Faculty of Medicine, Masaryk University; University Hospital Brno, Czech Republic (P Husa PhD); PAREXEL International, Research Triangle Park, NC, USA (D Shortino MS); GlaxoSmithKline, Stockley Park, Middlesex, UK (H A Watson MSc); GlaxoSmithKline, Stevenage, Herts, UK (P J Yates PhD); and GlaxoSmithKline, Boston, MA, USA (A F Peppercorn MD) Intravenous zanamivir or oral oseltamivir for hospitalised patients with infl uenza: an international, randomised, double-blind, double-dummy, phase 3 trial Article Title: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study Article Snippet: Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Hans Jaeger, Catherine Orrell, Firaya Nagimova, Fritz Bredeek, Miguel García Deltoro, Susan Swindells, Jaime Federico Andrade-Villanueva, Alexander Wong, Marie-Aude Khuong-Josses, Rodica Van Solingen-Ristea, Veerle van Eygen, Herta Crauwels, Susan Ford, Christine Talarico, Paul Benn, Yuanyuan Wang, Krischan J Hudson, Vasiliki Chounta, Amy Cutrell, Parul Patel, Mark Shaefer, David A Margolis, Kimberly Y Smith, Simon Vanveggel, William Spreen other:Article Title: Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study Article Snippet: Methods In this double-blind, randomised, dose-ranging phase 2b study, men and women (aged ≥16 years) with microscopically confi rmed P vivax monoinfection (parasite density >100 to <100 000 per μL blood) were enrolled from community health centres and hospitals across seven sites in Brazil, Peru, India, and Thailand.. Patients with glucose6-phosphate dehydrogenase enzyme activity of less than 70% were excluded.. Eligible patients received chloroquine (days 1−3) and were randomly assigned (1:1:1:1:1:1) by a computer-generated randomisation schedule to receive singledose tafenoquine 50 mg, 100 mg, 300 mg, or 600 mg, primaquine 15 mg for 14 days, or chloroquine alone. Article Title: Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial Article Snippet: Patients were randomised centrally across all sites in accordance with a |
